Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase NA 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 1056Neoplasms 890Prostatic Neoplasms 509Lung Neoplasms 426Colorectal Neoplasms 356Motor Activity 227Head and Neck Neoplasms 193Uterine Cervical Neoplasms 192Carcinoma, Non-Small-Cell Lung 182Brain Neoplasms 173Pancreatic Neoplasms 163Ovarian Neoplasms 141Colonic Neoplasms 138Carcinoma, Hepatocellular 136Anxiety Disorders 125Rectal Neoplasms 119Hematologic Neoplasms 115Multiple Myeloma 108Stomach Neoplasms 105Neoplasm Metastasis 100Precursor Cell Lymphoblastic Leukemia-Lymphoma 98Depression 94Melanoma 93Urinary Bladder Neoplasms 88Pain 88Endometrial Neoplasms 86Disease 85Lymphoma 84Glioblastoma 83Sarcoma 78

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Neoplasms, Nerve Tissue × 1 year × Clear all
NCT04446416 2026-04-09

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

NaviFUS Corporation

Phase NA Completed
6 enrolled
CNS

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡